Product Description: Glenzocimab (ACT017) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke[1][2].
Applications: Neuroscience-Neuromodulation
Formula: N/A
References: [1]Wichaiyo S, et al. Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke. Stroke. 2022 Nov;53(11):3506-3513. /[2]Lebozec K, et al. Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks. MAbs. 2017 Aug/Sep;9(6):945-958.
CAS Number: 2101829-58-5
Molecular Weight: N/A
Compound Purity: 95.00
Research Area: Cardiovascular Disease
Solubility: 10 mM in DMSO
Target: Others
English
Deutsch
